TrialBMC cancer2025

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.

Yanrong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.